Huntington Disease: Scientists Find New Clue to Earlier Onset

Scientists at the University of British Columbia have identified a genetic mechanism that may help explain why some people with Huntington disease develop symptoms years earlier and experience a more aggressive progression of the condition.

The study, led by researchers at UBC’s Centre for Molecular Medicine and Therapeutics and BC Children’s Hospital Research Institute, found that a genetic variant associated with earlier Huntington disease onset drives more frequent expansion of the disease-causing DNA mutation inside vulnerable brain neurons. The research was published in the journal Neuron on September 14, 2026.

The findings provide new evidence for the role of repeated DNA expansion in the progression of Huntington disease and point to a possible target for future treatments.

What is Huntington disease?

Huntington disease is an inherited neurological disorder caused by a mutation in the HTT gene.

The disease progressively damages nerve cells in the brain and can affect movement, thinking and emotional functioning.

People who inherit the disease-causing mutation can eventually develop symptoms, although the age at which symptoms begin can vary substantially.

Researchers have long known that the number of repeated DNA sequences in the HTT gene is related to when Huntington disease begins.

What has been harder to explain is why some people carrying particular genetic variants develop symptoms significantly earlier than others.

The new UBC study provides additional evidence about what happens inside the brain as the mutation changes over time.

Researchers investigated why symptoms can appear earlier

The UBC team focused on people carrying a genetic variant that is associated with substantially earlier Huntington disease onset.

According to the researchers, people with this variant can develop symptoms around 10 to 12 years earlier and experience a more aggressive form of the disease.

The researchers wanted to understand why a relatively small inherited genetic difference could have such a large effect on the timing and progression of the disease.

Their investigation pointed to a process known as somatic repeat expansion.

This refers to changes in the number of repeated DNA sequences that occur within individual cells during a person’s lifetime rather than being inherited as a new mutation from a parent.

The mutation can keep expanding inside neurons

The Huntington disease mutation contains repeated DNA sequences.

The researchers found evidence that these repeats can continue expanding inside neurons after the mutation has already been inherited.

The process can be compared to a copying error that becomes progressively longer each time it is reproduced.

In the vulnerable brain cells examined by the researchers, the mutation expanded much more extensively in people carrying the genetic variant associated with earlier disease onset.

The researchers reported that mutation expansion occurred approximately five times more frequently in people with the variant than in patients without it.

They also found fewer surviving neurons and earlier loss of particularly vulnerable nerve cells among people with the variant.

These findings strengthen the evidence that DNA repeat expansion is not simply a byproduct of Huntington disease but may be an important part of the process driving neuronal damage.

Why the brain is particularly affected

One of the longstanding questions surrounding Huntington disease is why a mutation present throughout the body primarily causes severe damage in the brain.

The UBC researchers found an important clue.

They examined blood samples as well as post-mortem brain tissue and found that the dramatic expansion of the mutation was concentrated in particular brain cells.

Blood samples showed little evidence of the same degree of expansion observed in vulnerable neurons.

This suggests that the disease-causing mutation behaves differently depending on the type of cell in which it is located.

The finding could also have implications for how researchers monitor Huntington disease in clinical studies.

If the important genetic changes are happening mainly inside vulnerable neurons, a blood test may not fully reflect what is happening inside the brain.

The researchers used human tissue

The study was not based solely on laboratory models.

The researchers analysed blood samples and post-mortem human brain tissue from people affected by Huntington disease.

They compared the genetic changes found in different tissues and examined how mutation expansion related to the survival of vulnerable neurons.

The researchers also investigated the biological process using experimental models to understand how the genetic variant influenced repeat expansion.

Combining these approaches allowed the team to connect observations in human disease tissue with a possible mechanism.

That is important because findings in laboratory models do not always reproduce what happens in human disease.

A potential treatment target

The findings could eventually influence the development of treatments for Huntington disease.

If repeated expansion of the mutation contributes directly to the destruction of vulnerable neurons, preventing or slowing that expansion could potentially delay disease progression.

The researchers described DNA repeat expansion as a potential therapeutic target.

Several experimental approaches are already being investigated with the goal of reducing or preventing expansion of the mutation.

However, the new study does not demonstrate that a treatment capable of stopping the process is currently available.

It also does not show that suppressing repeat expansion in patients will necessarily prevent symptoms or halt disease progression.

Those questions require further research and clinical testing.

Why the finding matters for drug development

Huntington disease has been particularly difficult to treat because its genetic cause is known but the biological processes connecting the mutation to progressive brain-cell death are complex.

Understanding those processes can help researchers identify points where treatment might intervene.

The new study adds evidence for a mechanism that occurs inside the neurons most vulnerable to Huntington disease.

If future research confirms that preventing repeat expansion can protect those cells, drugs designed to target that process could become part of the search for disease-modifying treatments.

For now, however, the research remains at the scientific discovery stage.

The findings also raise questions about disease monitoring

The difference between blood and brain tissue has another implication.

Researchers and drug developers often rely on measurable biological markers to determine whether a disease is progressing or whether an experimental treatment is having an effect.

If the most important mutation expansion occurs inside specific brain cells but is barely detectable in blood, measuring the process could be challenging.

The UBC researchers said their findings indicate that blood samples may not reliably show what is happening to the Huntington mutation inside the brain.

This could become important when researchers design future clinical trials.

A treatment might affect the underlying process in neurons without producing an obvious change in a blood-based measurement.

The discovery does not explain everything

The researchers are careful not to suggest that DNA expansion is the only factor involved in Huntington disease progression.

Other biological processes contribute to the loss of neurons and the development of symptoms.

The UBC team described repeat expansion as an important driver but acknowledged that additional factors are involved.

This distinction matters because scientific discoveries often identify one mechanism within a much larger biological system.

Finding an important mechanism does not automatically translate into an effective treatment.

Further research is needed to determine exactly how repeat expansion interacts with other processes involved in Huntington disease.

What comes next

The next stage will involve determining whether slowing mutation expansion can actually protect neurons and delay the development or progression of Huntington disease.

Researchers will need to establish how experimental treatments can safely target the process and whether the approach works in people.

The study provides a clearer biological explanation for why some patients develop Huntington disease much earlier than others, but it does not yet provide a clinical treatment.

The work could nevertheless help direct future research towards the genetic changes occurring inside vulnerable neurons.

A new piece of the Huntington disease puzzle

The UBC study adds another piece to scientists’ understanding of Huntington disease.

Researchers have known for years that the inherited HTT mutation is responsible for the condition. The new evidence helps explain how that mutation can continue changing inside vulnerable brain cells and why those changes may be associated with earlier and more aggressive disease.

The finding that mutation expansion is concentrated in particular brain neurons may also help explain why Huntington disease primarily damages the nervous system even though the mutation is present throughout the body.

The researchers now have a stronger basis for investigating whether preventing that expansion could alter the course of the disease.

For people affected by Huntington disease, that does not yet mean a new treatment is available. But for scientists, identifying a biological process that can potentially be targeted gives future research a more specific direction.